Pediatrix Medical Group (NYSE:MD) Price Target Raised to $16.50

Pediatrix Medical Group (NYSE:MD - Get Free Report) had its target price lifted by equities research analysts at UBS Group from $10.50 to $16.50 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has a "neutral" rating on the stock. UBS Group's price target would indicate a potential upside of 7.42% from the stock's current price.

Several other analysts also recently issued reports on MD. StockNews.com raised shares of Pediatrix Medical Group from a "sell" rating to a "hold" rating in a research report on Wednesday, August 7th. Truist Financial boosted their target price on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a "hold" rating in a research report on Monday. Deutsche Bank Aktiengesellschaft raised their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a "hold" rating in a research report on Monday. Jefferies Financial Group lifted their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a "buy" rating in a research note on Tuesday. Finally, Mizuho increased their price objective on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a "neutral" rating in a research note on Monday. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $16.10.

Pediatrix Medical Group Trading Up 1.5 %

Shares of MD stock traded up $0.22 during trading hours on Tuesday, hitting $15.36. 966,939 shares of the company were exchanged, compared to its average volume of 873,364. The company has a debt-to-equity ratio of 0.86, a quick ratio of 1.38 and a current ratio of 1.58. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $15.52. The company has a 50 day simple moving average of $11.70 and a two-hundred day simple moving average of $9.45. The firm has a market cap of $1.32 billion, a P/E ratio of -5.05, a P/E/G ratio of 2.36 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm had revenue of $511.20 million during the quarter, compared to the consensus estimate of $498.87 million. During the same period in the previous year, the firm posted $0.29 earnings per share. The business's revenue was up .9% compared to the same quarter last year. Equities analysts anticipate that Pediatrix Medical Group will post 1.19 EPS for the current year.

Insider Activity at Pediatrix Medical Group

In related news, CFO C Marc Richards sold 17,438 shares of the business's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $10.08, for a total value of $175,775.04. Following the transaction, the chief financial officer now directly owns 175,347 shares of the company's stock, valued at approximately $1,767,497.76. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Pediatrix Medical Group news, CEO James D. Swift sold 11,100 shares of the firm's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the sale, the chief executive officer now directly owns 170,001 shares of the company's stock, valued at $1,834,310.79. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO C Marc Richards sold 17,438 shares of the business's stock in a transaction on Monday, August 12th. The shares were sold at an average price of $10.08, for a total value of $175,775.04. Following the completion of the sale, the chief financial officer now owns 175,347 shares in the company, valued at approximately $1,767,497.76. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 68,100 shares of company stock valued at $701,889. 1.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its position in shares of Pediatrix Medical Group by 3.5% in the second quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company's stock valued at $245,000 after purchasing an additional 1,088 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Pediatrix Medical Group by 7.4% during the first quarter. ProShare Advisors LLC now owns 16,937 shares of the company's stock valued at $170,000 after buying an additional 1,167 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock valued at $36,000 after buying an additional 1,524 shares during the period. SummerHaven Investment Management LLC lifted its holdings in shares of Pediatrix Medical Group by 3.8% in the second quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company's stock worth $422,000 after buying an additional 2,069 shares in the last quarter. Finally, Bank of Montreal Can grew its stake in Pediatrix Medical Group by 0.5% during the second quarter. Bank of Montreal Can now owns 415,110 shares of the company's stock valued at $3,196,000 after acquiring an additional 2,083 shares in the last quarter. Institutional investors own 97.71% of the company's stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.